Kidney Week

Abstract: TH-PO282

Paricalcitol Treatment Upregulates Exosome-Derived Muscle Tissue-Specific MicroRNAs in Sarcopenic Male Patients on Hemodialysis

Session Information

• Hemodialysis and Frequent Dialysis - 1
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

• 801 Dialysis: Hemodialysis and Frequent Dialysis

Authors

• Park, Hyeong cheon, Division of Nephrology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (the Republic of)

Hyeong cheon Park, MD, PhD

• Choi, Hoon Young, Division of Nephrology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (the Republic of)

Hoon Young Choi, MD, PhD

• Kim, Hyung Jong, Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, Korea (the Republic of)

Hyung Jong Kim, MD, PhD

• Kim, Hyo Jeong, Division of Nephrology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (the Republic of)

Hyo Jeong Kim, MD

Background

Muscle tissue specific microRNAs (myomiRNAs) are special group of miRNAs that play important roles by targeting genes involved in muscle development, differentiation, and regeneration. Vitamin D administration has been reported to have beneficial effects on skeletal muscle. Aim was to compare myomiRNAs between sarcopenic and non-sarcopenic patients on hemodialysis treatment and assess the effects of paricalcitol treatment on their expression.

Methods

Fifty male patients undergoing hemodialysis were included in the study and were given paricalcitol (Alvogen Korea) according to KDIGO clinical practice guidelines for treatment of secondary hyperparathyroidism for 12 weeks. Skeletal muscle index (SMI) value was derived by bioimpedance measurement and study subjects were classified into sarcopenia (n=13) or non-sarcopenia (=37) according to the criteria of the Asian Working Group for Sarcopenia 2019. The patients’ blood derived exosomes were isolated and evaluated for expression of skeletal myomiRNAs (miR; miR-1, miR-133a, miR-206, miR-499), ), associated with enhanced skeletal muscle differentiation and myoblast proliferation, using real-time quantitative PCR.

Results

The mean age was 67.3 ± 10.8 years and mean hemodialysis vintage was 9.4±6.2 years. Mean SMI value was 6.0±0.4 and 7.4±0.4, respectively in sarcopenia and non-sarcopenia group. Sarcopenia group showed significantly decreased expression of exosomal myomiRNAs (miR-1, miR-133a, miR-206, miR-499) compared to non-sarcopenia group [RQ: relative quantification; mean, (standard deviation)]: 0.40 (0.13), 0.49 (0.10), 0.37 (0.08), and 0.43 (0.09) (p<0.01) Paricalcitol treatment for 12 weeks significantly increased expression of all exosomal myomiRNAs in sarcopenia group whereas non-sarcopenia group showed increase in miR-1, miR-133a, and miR-206. Interestingly, the response to paricalcitol treatment was independent of serum vitamin D levels.

Conclusion

Sarcopenic hemodialysis patients showed decreased myomiRNA expression for skeletal muscle differentiation and myoblast profliferation that was upregulated by short term vitamin D treatment. Therefore, vitamin D treatment may have beneficial roles in treatment of sarcopenia.